+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Neutropenia Treatment Market By Distribution channel, By Treatment, By Region, Industry Analysis and Forecast, 2020 - 2026

  • PDF Icon

    Report

  • 155 Pages
  • June 2020
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5129399
Description Jump to:
The Global Neutropenia Treatment Market size is expected to reach $18.9 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period. Neutropenia is an abnormal condition characterized by a critically low level of circulating neutrophils, a type of WBC found in the blood. These cells make up the majority of circulating lymphocytes and help protect the body from infections caused by bacteria, viruses, and other pathogenic organisms. A decrease in the amount of neutrophil in the blood allows a patient to be vulnerable to infection and can also prove fatal. The condition, therefore, requires immediate prophylaxis.

Novel treatments combined with growing cases of chemotherapy-induced neutropenia are one of the primary drivers of market growth. In addition, the novel drug delivery strategy also increases patient convenience, leading to greater adherence to the patient and thereby stimulates the growth of the market. Moreover, since cancer is a known cause of developing neutropenia, increasing cases of chemotherapy for cancer treatment will be a growth driver for the neutropenia treatment market.

One of the new developments to gain momentum in the global neutropenia treatment market is the introduction of small molecules. The development of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals with immune-boosting effects, is expected to revolutionize the therapeutic regimen for neutropenia. In addition to the immune-boosting effects, the Phase II studies have revealed much more beneficial anti-cancer effects of this molecule. Currently, there is a high demand for cost-effective drugs for treatment in the neutropenia treatment market. As a result, vendors are focused on the production of small molecules with lower processing costs than biologics.

Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.

Strategies deployed in Neutropenia Treatment Market

Jun-2020: Pfizer got FDA approval for NYVEPRIA (pegfilgrastim-apgf), a biosimilar to Neulasta (pegfilgrastim). NYVEPRIA is used for decreasing the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Apr-2020: Mylan collaborated with Biocon, a biopharmaceutical company. Together, the companies launched Fulphila, a biosimilar to Neulasta (pegfilgrastim) in Australia and Canada for cancer patients. Fulphila is used for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and reduce the incidence of infections, as manifested by febrile neutropenia. The companies got FDA approval for Fulphila in June, 2018.

Nov-2019: Sandoz, a Novartis division got FDA approval for Ziextenzo (pegfilgrastim-bmez). Ziextenzo has been used to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy.

Nov-2019: Teva Pharmaceuticals teamed up with Celltrion, Inc., a biopharmaceutical company. Together, the companies announced the launch of TRUXIMA (rituximab-abbs) injection. TRUXIMA is currently indicated for the treatment of adult patients with non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).

Jul-2019: Pfizer acquired Array BioPharma Inc., a pharmaceutical company. The acquisition strengthened Pfizer's innovative biopharmaceutical business and category leadership in Oncology expected acceleration of Pfizer’s long-term growth trajectory through new medicines.

Nov-2018: Partner Therapeutics announced that FDA has granted orphan drug designation to Leukine (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). This drug is used for the treatment of pulmonary alveolar proteinosis (PAP). Leukine works by stimulating the production of white blood cells including neutrophils, monocytes/macrophages and myeloid-derived dendritic cell and promoting their ability to function.

Jul-2018: Cellerant Therapeutics announced that FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for romyelocel-L (human myeloid progenitor cells) for the prevention of serious bacterial and fungal infections in patients with de novo acute myeloid leukemia (AML) undergoing induction chemotherapy.

Jul-2018: Pfizer announced that it received FDA approval for NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). This drug expanded the access to critical treatment options for patients with neutropenia.

Feb-2018: Partner Therapeutics signed an agreement with Sanofi. Following the agreement, the former company acquired the global rights for developing, manufacturing, and commercializing Leukine (sargramostim). Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body's immune response to fight infection.

Scope of the Study

Market Segmentation:

By Distribution Channel
  • Retail pharmacies
  • Hospital pharmacies and
  • Online pharmacies

By Treatment
  • Colony-stimulating factor
  • Antibiotics
  • Antifungals and
  • Antivirals

By Geography

North America
  • US
  • Canada
  • Mexico
  • Rest of North America

Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled
  • Amgen, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • BeyondSpring, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Mylan N.V.
  • Cellerant Therapeutics, Inc.
  • Partner Therapeutics, Inc.

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Neutropenia Treatment Market, by Distribution Channel
1.4.2 Global Neutropenia Treatment Market, by Treatment
1.4.3 Global Neutropenia Treatment Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Neutropenia Treatment Market by Distribution channel
3.1 Global Retail pharmacies Market by Region
3.2 Global Hospital pharmacies Market by Region
3.3 Global Online pharmacies Market by Region
Chapter 4. Global Neutropenia Treatment Market by Treatment
4.1 Global Colony-stimulating factor Market by Region
4.2 Global Antibiotics Market by Region
4.3 Global Antifungals Market by Region
4.4 Global Antivirals Market by Region
Chapter 5. Global Neutropenia Treatment Market by Region
5.1 North America Neutropenia Treatment Market
5.1.1 North America Neutropenia Treatment Market by Distribution channel
5.1.1.1 North America Retail pharmacies Market by Country
5.1.1.2 North America Hospital pharmacies Market by Country
5.1.1.3 North America Online pharmacies Market by Country
5.1.2 North America Neutropenia Treatment Market by Treatment
5.1.2.1 North America Colony-stimulating factor Market by Country
5.1.2.2 North America Antibiotics Market by Country
5.1.2.3 North America Antifungals Market by Country
5.1.2.4 North America Antivirals Market by Country
5.1.3 North America Neutropenia Treatment Market by Country
5.1.3.1 US Neutropenia Treatment Market
5.1.3.1.1 US Neutropenia Treatment Market by Distribution channel
5.1.3.1.2 US Neutropenia Treatment Market by Treatment
5.1.3.2 Canada Neutropenia Treatment Market
5.1.3.2.1 Canada Neutropenia Treatment Market by Distribution channel
5.1.3.2.2 Canada Neutropenia Treatment Market by Treatment
5.1.3.3 Mexico Neutropenia Treatment Market
5.1.3.3.1 Mexico Neutropenia Treatment Market by Distribution channel
5.1.3.3.2 Mexico Neutropenia Treatment Market by Treatment
5.1.3.4 Rest of North America Neutropenia Treatment Market
5.1.3.4.1 Rest of North America Neutropenia Treatment Market by Distribution channel
5.1.3.4.2 Rest of North America Neutropenia Treatment Market by Treatment
5.2 Europe Neutropenia Treatment Market
5.2.1 Europe Neutropenia Treatment Market by Distribution channel
5.2.1.1 Europe Retail pharmacies Market by Country
5.2.1.2 Europe Hospital pharmacies Market by Country
5.2.1.3 Europe Online pharmacies Market by Country
5.2.2 Europe Neutropenia Treatment Market by Treatment
5.2.2.1 Europe Colony-stimulating factor Market by Country
5.2.2.2 Europe Antibiotics Market by Country
5.2.2.3 Europe Antifungals Market by Country
5.2.2.4 Europe Antivirals Market by Country
5.2.3 Europe Neutropenia Treatment Market by Country
5.2.3.1 Germany Neutropenia Treatment Market
5.2.3.1.1 Germany Neutropenia Treatment Market by Distribution channel
5.2.3.1.2 Germany Neutropenia Treatment Market by Treatment
5.2.3.2 UK Neutropenia Treatment Market
5.2.3.2.1 UK Neutropenia Treatment Market by Distribution channel
5.2.3.2.2 UK Neutropenia Treatment Market by Treatment
5.2.3.3 France Neutropenia Treatment Market
5.2.3.3.1 France Neutropenia Treatment Market by Distribution channel
5.2.3.3.2 France Neutropenia Treatment Market by Treatment
5.2.3.4 Russia Neutropenia Treatment Market
5.2.3.4.1 Russia Neutropenia Treatment Market by Distribution channel
5.2.3.4.2 Russia Neutropenia Treatment Market by Treatment
5.2.3.5 Spain Neutropenia Treatment Market
5.2.3.5.1 Spain Neutropenia Treatment Market by Distribution channel
5.2.3.5.2 Spain Neutropenia Treatment Market by Treatment
5.2.3.6 Italy Neutropenia Treatment Market
5.2.3.6.1 Italy Neutropenia Treatment Market by Distribution channel
5.2.3.6.2 Italy Neutropenia Treatment Market by Treatment
5.2.3.7 Rest of Europe Neutropenia Treatment Market
5.2.3.7.1 Rest of Europe Neutropenia Treatment Market by Distribution channel
5.2.3.7.2 Rest of Europe Neutropenia Treatment Market by Treatment
5.3 Asia Pacific Neutropenia Treatment Market
5.3.1 Asia Pacific Neutropenia Treatment Market by Distribution channel
5.3.1.1 Asia Pacific Retail pharmacies Market by Country
5.3.1.2 Asia Pacific Hospital pharmacies Market by Country
5.3.1.3 Asia Pacific Online pharmacies Market by Country
5.3.2 Asia Pacific Neutropenia Treatment Market by Treatment
5.3.2.1 Asia Pacific Colony-stimulating factor Market by Country
5.3.2.2 Asia Pacific Antibiotics Market by Country
5.3.2.3 Asia Pacific Antifungals Market by Country
5.3.2.4 Asia Pacific Antivirals Market by Country
5.3.3 Asia Pacific Neutropenia Treatment Market by Country
5.3.3.1 China Neutropenia Treatment Market
5.3.3.1.1 China Neutropenia Treatment Market by Distribution channel
5.3.3.1.2 China Neutropenia Treatment Market by Treatment
5.3.3.2 Japan Neutropenia Treatment Market
5.3.3.2.1 Japan Neutropenia Treatment Market by Distribution channel
5.3.3.2.2 Japan Neutropenia Treatment Market by Treatment
5.3.3.3 India Neutropenia Treatment Market
5.3.3.3.1 India Neutropenia Treatment Market by Distribution channel
5.3.3.3.2 India Neutropenia Treatment Market by Treatment
5.3.3.4 South Korea Neutropenia Treatment Market
5.3.3.4.1 South Korea Neutropenia Treatment Market by Distribution channel
5.3.3.4.2 South Korea Neutropenia Treatment Market by Treatment
5.3.3.5 Singapore Neutropenia Treatment Market
5.3.3.5.1 Singapore Neutropenia Treatment Market by Distribution channel
5.3.3.5.2 Singapore Neutropenia Treatment Market by Treatment
5.3.3.6 Malaysia Neutropenia Treatment Market
5.3.3.6.1 Malaysia Neutropenia Treatment Market by Distribution channel
5.3.3.6.2 Malaysia Neutropenia Treatment Market by Treatment
5.3.3.7 Rest of Asia Pacific Neutropenia Treatment Market
5.3.3.7.1 Rest of Asia Pacific Neutropenia Treatment Market by Distribution channel
5.3.3.7.2 Rest of Asia Pacific Neutropenia Treatment Market by Treatment
5.4 LAMEA Neutropenia Treatment Market
5.4.1 LAMEA Neutropenia Treatment Market by Distribution channel
5.4.1.1 LAMEA Retail pharmacies Market by Country
5.4.1.2 LAMEA Hospital pharmacies Market by Country
5.4.1.3 LAMEA Online pharmacies Market by Country
5.4.2 LAMEA Neutropenia Treatment Market by Treatment
5.4.2.1 LAMEA Colony-stimulating factor Market by Country
5.4.2.2 LAMEA Antibiotics Market by Country
5.4.2.3 LAMEA Antifungals Market by Country
5.4.2.4 LAMEA Antivirals Market by Country
5.4.3 LAMEA Neutropenia Treatment Market by Country
5.4.3.1 Brazil Neutropenia Treatment Market
5.4.3.1.1 Brazil Neutropenia Treatment Market by Distribution channel
5.4.3.1.2 Brazil Neutropenia Treatment Market by Treatment
5.4.3.2 Argentina Neutropenia Treatment Market
5.4.3.2.1 Argentina Neutropenia Treatment Market by Distribution channel
5.4.3.2.2 Argentina Neutropenia Treatment Market by Treatment
5.4.3.3 UAE Neutropenia Treatment Market
5.4.3.3.1 UAE Neutropenia Treatment Market by Distribution channel
5.4.3.3.2 UAE Neutropenia Treatment Market by Treatment
5.4.3.4 Saudi Arabia Neutropenia Treatment Market
5.4.3.4.1 Saudi Arabia Neutropenia Treatment Market by Distribution channel
5.4.3.4.2 Saudi Arabia Neutropenia Treatment Market by Treatment
5.4.3.5 South Africa Neutropenia Treatment Market
5.4.3.5.1 South Africa Neutropenia Treatment Market by Distribution channel
5.4.3.5.2 South Africa Neutropenia Treatment Market by Treatment
5.4.3.6 Nigeria Neutropenia Treatment Market
5.4.3.6.1 Nigeria Neutropenia Treatment Market by Distribution channel
5.4.3.6.2 Nigeria Neutropenia Treatment Market by Treatment
5.4.3.7 Rest of LAMEA Neutropenia Treatment Market
5.4.3.7.1 Rest of LAMEA Neutropenia Treatment Market by Distribution channel
5.4.3.7.2 Rest of LAMEA Neutropenia Treatment Market by Treatment
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.10 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:

Companies Mentioned

  • Amgen, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • BeyondSpring, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Mylan N.V.
  • Cellerant Therapeutics, Inc.
  • Partner Therapeutics, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Global Neutropenia Treatment Market by Treatment (Antibiotics, Antifungals, Antivirals), Distribution Channel (Hospital pharmacies, Online pharmacies, Retail pharmacies) - Forecast 2024-2030 - Product Image

Global Neutropenia Treatment Market by Treatment (Antibiotics, Antifungals, Antivirals), Distribution Channel (Hospital pharmacies, Online pharmacies, Retail pharmacies) - Forecast 2024-2030

  • Report
  • 191 Pages
  • Global
From
Global Neutropenia Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global Neutropenia Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 199 Pages
  • Global
From
Neutropenia Biologic Drug Treatment Global Market Report 2024 - Product Image

Neutropenia Biologic Drug Treatment Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Chemotherapy Induced Neutropenia - Pipeline Insight, 2024 - Product Image

Chemotherapy Induced Neutropenia - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Neutropenia - Pipeline Insight, 2024 - Product Image

Neutropenia - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.